This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …

Post-transplant lymphoproliferative diseases (PTLD) are heterogeneous lymphoid disorders
ranging from indolent polyclonal proliferations to aggressive lymphomas that complicate …

These updated guidelines from the American Society of Transplantation Infectious Diseases
Community of Practice review the diagnosis, management, and prevention of post …

Background In previous analyses of BENEFIT, a phase 3 study, belatacept-based
immunosuppression, as compared with cyclosporine-based immunosuppression, was …

Iatrogenic immunosuppression is a unique setting for investigating immune‐related
mechanisms of carcinogenesis. Solid organ transplant recipients have a 3‐fold excess risk …

Post-transplant malignancy is recognised as being a major limitation to the success of solid
organ transplantation and it is currently considered one of the unavoidable costs of long …

Purpose Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-
year overall survival (OS) of 35% to 40%. The impact of rituximab on the outcome of PTLD is …

In kidney transplant recipients, cancer is one of the leading causes of death with a
functioning graft beyond the first year of kidney transplantation, and malignancies account …

Epstein-Barr virus (EBV) is a ubiquitous herpes virus that infects the majority of the
population worldwide. The virus can establish a lifelong latent infection in host B …

We examined the associations of Epstein–Barr virus (EBV) status with characteristics and
outcomes of posttransplantation lymphoproliferative disorder (PTLD) by studying 176 adult …